A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants with HIV-1 Virologically Suppressed on Antiretroviral Therapy

  • Schmidt, Tina (Primary Chief Investigator (PCI))
  • Silvers, Julie (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date5/06/20 → 31/12/22
View all
View less

Keywords

  • Infectious diseases
  • Human immunodeficiency virus (HIV)
  • Clinical trial